New clinical trial tests safety and efficacy of combination therapy in ovarian cancer and other women's malignancies

Posted: Nov 9, 2016

The Center for Cancer Research has opened a new clinical trial in ovarian cancer that will test the safety and efficacy a therapy combining two drugs.   The phase I trial will test a combination therapy for ovarian, fallopian tube, and peritoneal cancers and is enrolling patients at the NIH Clinical Center. Learn more...

 

New clinical trial tests safety and efficacy of combination therapy in ovarian cancer and other women's malignancies

Fighting liver cancer with combination immunotherapies

Posted: Oct 21, 2016

A new clinical trial testing the effectiveness of immunotherapy treatment combinations against liver cancer is enrolling patients at the NIH Clinical Center in Bethesda, Maryland. Individually, immunotherapy drugs harness the power of the human immune system to better identify and kill cancer cells. Now, researchers at the NIH’s Center for Cancer Research have begun to find evidence that the drugs may work far more effectively when taken in combination with other therapies and with each other than when taken alone.

Fighting liver cancer with combination immunotherapies

ETIB opens clinical trial for patients with HPV-16+ cancers

Posted: Sep 28, 2016

Dr. Christian Hinrichs, Lasker Clinical Research Scholar in the Experimental Transplantation and Immunology Branch, is leading a study of a new therapy for cancers caused by human papillomavirus (HPV), which include cervical, throat, anal, and genital cancers. HPV-related cancer cells carry a protein called E7.  Learn more...

ETIB opens clinical trial for patients with HPV-16+ cancers

ETIB tests safety and effectiveness of Baricitinib for chronic GVHD

Posted: Sep 28, 2016

The Center for Cancer Research has launched a new clinical trial focusing on improving the treatment of chronic graft-versus-host disease, a common adverse reaction that may develop after certain bone marrow transplants.  Learn more...

ETIB tests safety and effectiveness of Baricitinib for chronic GVHD

Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

Posted: Sep 26, 2016

Thomas Uldrick, senior clinician in the HIV and AIDS Malignancy Branch, has launched a new phase 1 trial evaluating the immunotherapy drug Keytruda, which is designed to target cancer cells in HIV-positive cancer patients. Cancer Today reported that many HIV-positive patients with cancer do not get proper treatment for their cancers, and Uldrick hopes the drug will kill both cancer cells and HIV cells.

Thomas Uldrick discusses new immunotherapy trial in Cancer Today magazine

New clinical trial will test COXEN’s ability to choose best therapy for patients with advanced bladder cancer

Posted: Sep 13, 2016

The Genitourinary Malignancies Branch is now enrolling participants for a clinical trial that will evaluate whether analyzing a tumor’s genetic profile can identify which approved anticancer drugs are most likely to benefit individual patients whose bladder cancer has stopped responding to standard treatments. Learn more...

New clinical trial will test COXEN’s ability to choose best therapy for patients with advanced bladder cancer

Pages